Extended Data Fig. 2: CSF1R and CD86 are consistently expressed across multiple patients with differing molecular subtypes.

(a, c) Amount of malignant and normal cells per AML patient of van Galen et al. (a) or Petti et al. (c). (b, d) Percentage of malignant and normal cells expressing target genes CSF1R, CD86 and reference genes CD123, CD33 for each sequenced AML patient of van Galen et al. (b) or Petti et al. (d). (e) Data from van Galen et al.²¹ was used as a reference (top left) to map cells from Petti et al.³⁹ (top right) using scANVI⁴⁰. UMAP representation showing the mapped query and reference data together (bottom). (f) Computational CAR target antigen identification using the mapped dataset of Petti et al. by stepwise evaluation against a set of criteria for an ideal and effective CAR target antigen. The decreasing number of screened AML target genes are shown on the bottom. CSPA: Cell surface protein atlas; HPA: Human protein atlas. (g) Volcano plot showing CD86 and CSF1R target genes with their respective FDR-adjusted log₁₀ p-value and log₂ fold changes from differential expression analysis between malignant HSPC-like and healthy HSPC using a t-test with overestimated variance.